Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.48 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.48 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4393888 | 1.00 | MAPT (0.54) | MAPTTHRBALDH1A1KMT2AMEN1 | |
| SCHEMBL7188544 | 0.82 | MAPK1 (0.55) | MAPTTHRBALDH1A1KMT2AMEN1 | |
| SCHEMBL1855648 | 0.81 | MAPT (0.50) | MAPTTHRBALDH1A1KMT2AMEN1 | |
| SCHEMBL1855646 | 0.81 | MAPT (0.50) | MAPTTHRBALDH1A1KMT2AMEN1 | |
| SCHEMBL27756751 | 0.79 | KMT2A (0.48) | MAPTTHRBALDH1A1KMT2AMEN1 | |
| SCHEMBL4395374 | 0.79 | KAT2B (0.47) | MAPTALDH1A1KMT2AMEN1CYP3A4 | |
| SCHEMBL4395379 | 0.79 | KAT2B (0.47) | MAPTALDH1A1KMT2AMEN1CYP3A4 | |
| SCHEMBL7192206 | 0.78 | KMT2A (0.52) | MAPTTHRBALDH1A1KMT2AMEN1 | |
| SCHEMBL27756747 | 0.78 | MAPT (0.47) | MAPTTHRBALDH1A1KMT2AMEN1 | |
| SCHEMBL116538 | 0.77 | MAPK1 (0.62) | MAPTALDH1A1KMT2AMEN1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306068-A1 | NOVEL ENANTIOMERIC PURE BETA AGONISTS, MANUFACTURING AND USE AS A MEDICAMENTS THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-10 | — | — | US | disclosed |
| US-7429583-B2 | Betamimetics for the treatment of respiratory complaints | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-09-30 | — | — | US | disclosed |
| CN-101039937-A | Heteroaryl compounds for use as betamimetics in the treatment of respiratory diseases | BOEHRINGER INGELHEIM INT (DE) | 2007-09-19 | — | — | CN | disclosed |
| US-20060063817-A1 | New betamimetics for the treatment of respiratory complaints | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063817-A1 | New betamimetics for the treatment of respiratory complaints | CHRM1, ADRB1, ADRA1B | MAPT 4288/4885THRB 241/4885ALDH1A1 1726/4885 |
| US-20090306068-A1 | NOVEL ENANTIOMERIC PURE BETA AGONISTS, MANUFACTURING AND USE AS A MEDICAMENTS THEREOF | ADRB1, ADRB2, ADRA1B | MAPT 3907/4885THRB 161/4885ALDH1A1 2339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.